Insights into the pathophysiology of autoimmune inflammatory diseases including psoriasis have advanced considerably in recent years, and in parallel, so too have the available treatment options. Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic therapies, starting with tumour necrosis factor-alpha (TNF-a) inhibitors and later, agents targeting interleukin (IL)-12/23 and IL-17. The most recent evidence suggests that IL-23 might be an even more potent target for the effective treatment of psoriasis and other autoimmune inflammatory disorders. This review will describe recent developments leading to the current understanding of the key role of IL-23 as a 'master regulator' of autoimmune inflammation and the clinical evidence for agents that specifically target this modulator in the context of treating psoriasis, spondyloarthropathy and inflammatory bowel disease.
Introduction
Psoriasis was originally believed to be a disease originating from dysregulation of keratinocyte proliferation ( Fig. 1 ) based on histological evidence. 1, 2 Through the 1980-90s, evidence pointed to psoriasis as an immune-mediated disease. [3] [4] [5] Cytotoxic T cells were identified around capillaries 3 and within the dermis and epidermis 4 of psoriatic lesions. That T-cell-targeted therapies improved psoriasis outcomes further solidified this role in the disease pathophysiology. 6, 7 Subpopulations of T cells, T helper 1 (Th1) and T helper 2 (Th2) cells were identified based on their cytokine secretory profile. 8, 9 Th1 cells secrete interferon (IFN)-c, tumour necrosis factor (TNF)-a and interleukin (IL)-2, whereas Th2 cells secrete IL-4, -5, -10 and -13. 8, 9 Differentiation of na€ ıve T cells is cytokine-dependent: IL-12 driving Th1 cell differentiation 10 and IL-2 and -4 driving Th2 differentiation.
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With this increased understanding, psoriasis was deemed a Th1-mediated disease, as elevated levels of TNF-a 12 and the p40 subunit of IL-12 13 were identified in psoriatic lesions. These data supported the clinical development of TNF-a blockers as biologic treatments for psoriasis. 14 Subsequently, IL-23 was discovered comprised of a unique p19 subunit and sharing the p40 subunit of IL-12. 15 This shared subunit suggested that IL-23, and perhaps not IL-12, could play a role in the pathogenesis of psoriasis. The p40 and p19 subunits of IL-23, but not the p35 subunit of IL-12, are elevated in multiple forms of psoriasis, 13 75 response rates (71-83% at 12 weeks). [29] [30] [31] Anti-IL-17A biologics have also been shown to improve symptoms of psoriatic arthritis, 32, 33 ankylosing spondylitis 34 and rheumatoid arthritis. 35 In Phase II studies of patients with IBD, blocking IL-17A was ineffective. In fact, a worsening of the Crohn's disease was observed in some cases. 36, 37 One hypothesis for this observation is that the gut microbiotic environment may be contributing to the pathophysiology of this disease. 36 In addition, studies have shown that IL-17 plays a role in maintenance of the intestinal epithelial barrier and in tissue repair. 38, 39 A fourth IL-17 inhibitor, bimekizumab, which targets both IL-17A/F, is in early stages of clinical development. 40 Systemic downregulation of IL-17 has been associated with adverse effects related to the key role of IL-17 in protecting the skin and mucous membranes from infection, specifically candidiasis. 41 In clinical trials, approximately 2-4% of patients treated with IL-17 blockers developed candidiasis, mostly oral infections. 41 Case reports of suicidal ideation and completed suicides have been reported in patients taking brodalumab, 42 although a recent review of the evidence suggests that this may not be directly related to the drug itself. 43 Cases of IBD flare or new onset IBD have been reported in a small proportion of psoriasis patients exposed to ixekizumab (0.29 per 100 patientyears) 44 or secukinumab (0.33 per 100 patient-years) 45 ROR-ct. 55 Together, these observations highlight the fundamen- Targeting IL-23 instead of TNF-a may also confer a benefit in terms of risk of tuberculosis or hepatitis reactivation, as well as 'paradoxical psoriasis' or psoriasiform eruption. 63 It has been speculated that paradoxical psoriasis arises from a cytokine imbalance that favours dendritic cell activation and the unopposed production of IFN-a. 63 (Fig. 3) . A growing body of the literature supports a central role of IL-23 in the pathophysiology of spondyloarthropathy. Cells harbouring IL-23 receptors have been identified in the entheses and have been shown to induce the production of pro-inflammatory IL-17. 70 In a murine model, administration of IL-23 resulted in entheseal inflammatory arthritis and bone erosion similar to spondyloarthritis. 71 The same gene polymorphisms in the IL-23 receptor associated with psoriasis have been shown to be associated with psoriatic arthritis 72 and ankylosing spondylitis. 73 Murine IBD models have shown that IL-23 is a requirement for the induction of intestinal mucosal inflammation. 74 Elevated transcription of IL-23 has been found in the inflamed mucosa of patients with Crohn's disease, with a dose-dependent effect on disease severity. 75 Studies suggest that blocking IL-23 does not impair IL-17 production by innate non-T-cell lymphocytes 76 thereby preserving intestinal epithelial integrity and tissue repair mechanisms. 38, 39 These data support a unifying aspect of IL-23 in the pathophysiology of autoinflammatory diseases and suggest that targeting IL-23 may present a common approach to the treatment of diseases including psoriasis, IBD and spondyloarthropathy which are often overlapping (Fig. 4) . 77 
Clinical data support a principal role for IL-23 in psoriasis
Understanding the pathophysiology of disease may identify therapeutic targets. Conversely, the clinical application of targeted therapies provides information about the mechanisms underlying disease. The clinical development of anti-IL-23p19 drugs for psoriasis will be described below.
Guselkumab
A Phase I study examined the safety, efficacy and biomarker response of a single dose of guselkumab in 24 patients with psoriasis. 56 Blocking IL-23 modulated the expression of several genes in psoriatic skin lesions including IL-17A, IL-17F and CXCL1 with limited effects on the Th1 pathway and decreased levels of circulating IL-17A, likely due to a reduction in the number and/or activity of pathogenic Th17 cells. Reductions in levels of other cytokines including IL-17F, IL-22 and TNF-a did not reach statistical significance. In a Phase II study, varying doses of guselkumab (i.e. 5, 15, 50, 100 and 200 mg) were compared to placebo (weeks 0-16) and to adalimumab (weeks 0-52). 78 For all efficacy measures, dose-response improvements in the guselkumab-treated groups were greater than placebo. 78 Clinical improvements in the guselkumab-treated groups peaked at~20 weeks and were maintained through 40 weeks. 78 The incidence of adverse effects was low, with similar rates of infection in the placebo, guselkumab and adalimumab arms. The VOYAGE-1 Phase III trial confirmed the superiority of guselkumab over placebo and adalimumab (PASI 90 response rates 73.3%, 2.9% and 49.7%, respectively). 79 Adverse event rates in this trial were also similar between treatment groups. 79 In VOYAGE-2, adalimumab non- 81 Guselkumab has been shown to reduce IL-17 levels in blood and psoriatic lesions, supporting a causal relation between a reduction in the number, or activity, of Th17 cells and clinical improvements in psoriasis. 56 
Tildrakizumab
In a Phase IIb trial, tildrakizumab 5, 25, 100 and 200 mg was compared to placebo for 52 weeks. 82 The PASI 75 response rate (primary endpoint) was significantly higher in tildrakizumab-treated patients compared to placebo by week 16 (33-74% compared to 4% for placebo; P < 0.001 vs. placebo for all doses) and was generally maintained through 52 weeks. 82 PASI 90 rates were 12-52% at week 16, and 73-81% of week 16 responders maintained PASI 90 at week 52. 82 Adverse events were similar between active treatment and placebo groups. 82 The Phase III trial, reSUR-FACE-1, confirmed these results (PASI 75 response rates ranged from 62% to 64% at week 12 and 80% to 82% at week 28). 83 In reSURFACE-2, 37-39% of patients treated with tildrakizumab achieved PASI 90 at 28 weeks compared to 21% with etanercept and 1% with placebo. 83 Adverse events were similarly low between tildrakizumab and etanercept. 
Risankizumab
In a Phase I trial, PASI 75, 90 and 100 response rates were significantly higher in the risankizumab group compared to placebo at 12 weeks (87%, 58%, 16% and 0%, respectively), and responses were maintained through 24 weeks. 84 Adverse events
were not different between treatment and placebo groups. 84 Significant reductions in IL-23, IL-23R and IL-17 were demonstrated in lesional skin biopsies with active treatment compared to control. 85 In a Phase II trial, risankizumab was superior to ustekinumab in the proportion of patients achieving PASI 90 (77% vs. 40%; P < 0.001 pooled risankizumab groups vs. ustekinumab). 85 Adverse events were similar between treatments. 89 Clinical data in the investigation of rheumatoid diseases (i.e. psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis) have reported varying results. Significant improvements in symptoms, physical function and quality of life were observed with guselkumab in psoriatic arthritis patients. 90 Ustekinumab reduced signs and symptoms of ankylosing spondylitis in a proof-of-concept study. 91 In contrast, Figure 4 Unifying concept of IL-23 as a 'master regulator' in the pathogenesis of autoimmune disorders. Psoriasis, rheumatoid diseases and inflammatory bowel disease are all characterized by the pathogenic overproduction of IL-23 at barrier sites, i.e. the skin, the joints and the gut, respectively. This makes IL-23 an attractive target for all three conditions. IBD, inflammatory bowel disease; IL, interleukin; Th, T-helper cell.
neither ustekinumab nor guselkumab was effective at reducing signs and symptoms of active rheumatoid arthritis. 92 Mixed results have also been reported in other inflammatory diseases. Ustekinumab, risankizumab and MEDI2070 (anti-p19 monoclonal antibody) have demonstrated effectiveness for the treatment of Crohn's disease. [93] [94] [95] Ustekinumab was not effective in treating symptoms of multiple sclerosis, although it was well tolerated. 96 
Conclusions
Psoriasis is recognized as a Th17-mediated inflammatory disorder. A growing body of evidence supports IL-23 as the 'master regulator' of the immune-inflammatory response in psoriasis and other inflammatory disorders due to its critical role in maintaining the population of cytotoxic Th17 cells that produce pro-inflammatory cytokines including IL-17 and IL-22. Emerging results of randomized clinical trials suggest that selectively blocking IL-23 (p19 subunit) offers benefits above and beyond current treatment strategies for psoriasis producing high levels of efficacy, a favourable safety/tolerability profile, and the convenience of infrequent dosing. IL-23 blockers represent an important step forward in the continued evolution of the treatment landscape. Patients with psoriasis and other inflammatory diseases can expect better outcomes as therapies become more targeted and refined.
